LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.

Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L

The Prostate13 Oct 2010Cited by 64 (Europe PMC)

PMID20945403DOI10.1002/pros.21289PepBankPUB-20945403

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats with BPH, cetrorelix significantly reduced the listed inflammatory cytokine and growth factor mRNA levels versus vehicle.
In plain wordsIn rats with BPH, cetrorelix reduced the listed inflammatory cytokine and growth factor mRNA levels versus vehicle.
Peptide
Cetrorelix
Outcome
DecreaseInflammatory cytokine and growth factor mRNA
Study
ratn: not reported in source
Testosterone enanthate-induced benign prostatic hyperplasia in adult male Wistar rats
Comparator
TE-control rats receiving vehicle
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
0.625 mg/kg on days 1 and 22As given in this study (rat).
Measurements
P value
< 0.05
Listed cytokine and growth factor mRNA
Source sentences
Summary
mRNA levels for inflammatory cytokines IFN-γ, IL-3, IL-4, IL-5, IL-6, IL-8, IL-13, IL-15, and IL-17 and for growth factors EGF, FGF-2, FGF-7, FGF-8, FGF-14, TGF-β1, and VEGF-A were significantly reduced by Cetrorelix 0.625 mg/kg (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were used.
Summary · context
BPH was induced in rats by subcutaneous injections of TE 2 mg/day for 4 weeks.
Summary · context
After induction of BPH, rats received depot Cetrorelix pamoate at the doses of 0.625, 1.25, and 12.5 mg/kg on days 1 and 22 and TE-control rats received vehicle injections.
Report a problemFND-2094540301
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with BPH, cetrorelix at 0.625 mg/kg significantly lowered prostate weights compared with vehicle.
In plain wordsIn rats with BPH, cetrorelix at 0.625 mg/kg lowered prostate weights compared with vehicle.
Peptide
Cetrorelix
Outcome
DecreaseProstate weight
Study
ratn: not reported in source
Testosterone enanthate-induced benign prostatic hyperplasia in adult male Wistar rats
Comparator
TE-control rats receiving vehicle
Outcome group
Prostate Size · Kidney and urinary
Studied dose
0.625 mg/kg on days 1 and 22As given in this study (rat).
Source sentences
Summary
Prostate weights were also significantly lowered by any dose of Cetrorelix.
3 context sentences(design, population, supporting numbers)
Summary · context
After induction of BPH, rats received depot Cetrorelix pamoate at the doses of 0.625, 1.25, and 12.5 mg/kg on days 1 and 22 and TE-control rats received vehicle injections.
Summary · context
Adult male Wistar rats were used.
Summary · context
BPH was induced in rats by subcutaneous injections of TE 2 mg/day for 4 weeks.
Report a problemFND-2094540302
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with BPH, cetrorelix at 1.25 mg/kg significantly lowered prostate weights compared with vehicle.
In plain wordsIn rats with BPH, cetrorelix at 1.25 mg/kg lowered prostate weights compared with vehicle.
Peptide
Cetrorelix
Outcome
DecreaseProstate weight
Study
ratn: not reported in source
Testosterone enanthate-induced benign prostatic hyperplasia in adult male Wistar rats
Comparator
TE-control rats receiving vehicle
Outcome group
Prostate Size · Kidney and urinary
Studied dose
1.25 mg/kg on days 1 and 22As given in this study (rat).
Source sentences
Summary
Prostate weights were also significantly lowered by any dose of Cetrorelix.
3 context sentences(design, population, supporting numbers)
Summary · context
After induction of BPH, rats received depot Cetrorelix pamoate at the doses of 0.625, 1.25, and 12.5 mg/kg on days 1 and 22 and TE-control rats received vehicle injections.
Summary · context
Adult male Wistar rats were used.
Summary · context
BPH was induced in rats by subcutaneous injections of TE 2 mg/day for 4 weeks.
Report a problemFND-2094540303
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with BPH, cetrorelix at 12.5 mg/kg significantly lowered prostate weights compared with vehicle.
In plain wordsIn rats with BPH, cetrorelix at 12.5 mg/kg lowered prostate weights compared with vehicle.
Peptide
Cetrorelix
Outcome
DecreaseProstate weight
Study
ratn: not reported in source
Testosterone enanthate-induced benign prostatic hyperplasia in adult male Wistar rats
Comparator
TE-control rats receiving vehicle
Outcome group
Prostate Size · Kidney and urinary
Studied dose
12.5 mg/kg on days 1 and 22As given in this study (rat).
Source sentences
Summary
Prostate weights were also significantly lowered by any dose of Cetrorelix.
3 context sentences(design, population, supporting numbers)
Summary · context
After induction of BPH, rats received depot Cetrorelix pamoate at the doses of 0.625, 1.25, and 12.5 mg/kg on days 1 and 22 and TE-control rats received vehicle injections.
Summary · context
Adult male Wistar rats were used.
Summary · context
BPH was induced in rats by subcutaneous injections of TE 2 mg/day for 4 weeks.
Report a problemFND-2094540304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.